Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, Tolerability and Safety, of Copaxone to That of High Dose Interferon (Betaseron or Rebif) in the Treatment of Relapsing Multiple Sclerosis Patients

Next Previous
X
Search
Trial Profile

A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, Tolerability and Safety, of Copaxone to That of High Dose Interferon (Betaseron or Rebif) in the Treatment of Relapsing Multiple Sclerosis Patients

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glatiramer acetate (Primary) ; Interferon beta-1a; Interferon beta-1b
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries

    • Most Recent Events

    • 09 Nov 2008 'Teva Pharmaceutical Industries' added as reported by ClinicalTrials.gov.
    • 09 Nov 2008 Actual patient number (91) added as reported by ClinicalTrials.gov.
    • 09 Nov 2008 Status changed from completed to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top